Admission of Shares to Official List
7 February 2023
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Admission of Shares to Official List
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has applied to the Financial Conduct Authority to admit 2 ordinary shares of 1 pence each in the Company to the Official List in relation to a historical transaction. It is expected that the shares will be admitted on or around 8 February 2023. The total issued share capital of the Company will remain 1,141,999,321 ordinary shares of 1 pence each, none of which are held in treasury.
Enquiries:
|
Hemogenyx Pharmaceuticals plc |
|
|
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder |
|
|
Peter Redmond, Director |
|
|
|
|
|
SP Angel Corporate Finance LLP |
Tel: +44 (0)20 3470 0470 |
|
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
|
|
Peterhouse Capital Limited |
Tel: +44 (0)20 7469 0930 |
|
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 3 hours ago Churchill China
- 3 hours ago Churchill China
- 3 hours ago Redx Pharma
- 3 hours ago Henderson High Income Trust
- 3 hours ago Gamma Communications